Asad Ullah, Abdul Qahar Khan Yasinzai, Hannah Chaudhury, Abdullah Chandasir, Tena Nguyen, Katharine Tracy, Agha Wali, Aman Goyal, Bisma Tareen, Hritvik Jain, Abdul Waheed, Asif Iqbal, Marjan Khan, Michelle Tarbox, Amir Humza Sohail
{"title":"原发性皮肤平滑肌肉瘤:美国人群手术治疗的人口统计学和生存效益。","authors":"Asad Ullah, Abdul Qahar Khan Yasinzai, Hannah Chaudhury, Abdullah Chandasir, Tena Nguyen, Katharine Tracy, Agha Wali, Aman Goyal, Bisma Tareen, Hritvik Jain, Abdul Waheed, Asif Iqbal, Marjan Khan, Michelle Tarbox, Amir Humza Sohail","doi":"10.1080/08998280.2025.2491895","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Leiomyosarcoma of the skin is a rare malignant mesenchymal neoplasm categorized as cutaneous or subcutaneous. This study identified demographic and pathological factors affecting the prognosis and treatment of leiomyosarcoma of the skin.</p><p><strong>Methods: </strong>Data of patients with skin leiomyosarcoma was extracted from 2000 to 2020 using the Surveillance, Epidemiology, and End Results database. Propensity score matching and prognostic nomograms were used to analyze survival rate predictions.</p><p><strong>Results: </strong>Most patients were >65 years of age (50.5%), male (78.8%), and White (88.5%). The overall 5-year survival was 79.9% (95% confidence interval [CI] = 77.4-82.6), and the 5-year cause-specific survival rate was 95.7% (95% CI = 94.2-97.2). Based on treatment, the 5-year cause-specific survival rate was 82.9% (95% CI = 80.3-85.6) for surgery only, 60.2% (95% CI = 47.7-76.0) for both radiation and surgery, and 68.2% (95% CI = 58.9-78.9) for no treatment. Multivariable analysis showed that head and neck tumors were associated with worse mortality.</p><p><strong>Conclusion: </strong>The results provide valuable insights that could shape development of future clinical protocols for skin leiomyosarcoma and impact patient care and treatment efficacy.</p>","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"399-406"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184114/pdf/","citationCount":"0","resultStr":"{\"title\":\"Primary cutaneous leiomyosarcoma: demographics and survival benefit of surgical management in a US population.\",\"authors\":\"Asad Ullah, Abdul Qahar Khan Yasinzai, Hannah Chaudhury, Abdullah Chandasir, Tena Nguyen, Katharine Tracy, Agha Wali, Aman Goyal, Bisma Tareen, Hritvik Jain, Abdul Waheed, Asif Iqbal, Marjan Khan, Michelle Tarbox, Amir Humza Sohail\",\"doi\":\"10.1080/08998280.2025.2491895\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Leiomyosarcoma of the skin is a rare malignant mesenchymal neoplasm categorized as cutaneous or subcutaneous. This study identified demographic and pathological factors affecting the prognosis and treatment of leiomyosarcoma of the skin.</p><p><strong>Methods: </strong>Data of patients with skin leiomyosarcoma was extracted from 2000 to 2020 using the Surveillance, Epidemiology, and End Results database. Propensity score matching and prognostic nomograms were used to analyze survival rate predictions.</p><p><strong>Results: </strong>Most patients were >65 years of age (50.5%), male (78.8%), and White (88.5%). The overall 5-year survival was 79.9% (95% confidence interval [CI] = 77.4-82.6), and the 5-year cause-specific survival rate was 95.7% (95% CI = 94.2-97.2). Based on treatment, the 5-year cause-specific survival rate was 82.9% (95% CI = 80.3-85.6) for surgery only, 60.2% (95% CI = 47.7-76.0) for both radiation and surgery, and 68.2% (95% CI = 58.9-78.9) for no treatment. Multivariable analysis showed that head and neck tumors were associated with worse mortality.</p><p><strong>Conclusion: </strong>The results provide valuable insights that could shape development of future clinical protocols for skin leiomyosarcoma and impact patient care and treatment efficacy.</p>\",\"PeriodicalId\":8828,\"journal\":{\"name\":\"Baylor University Medical Center Proceedings\",\"volume\":\"38 4\",\"pages\":\"399-406\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184114/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Baylor University Medical Center Proceedings\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/08998280.2025.2491895\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Baylor University Medical Center Proceedings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/08998280.2025.2491895","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
背景:皮肤平滑肌肉瘤是一种罕见的恶性间质肿瘤,可分为皮肤或皮下。本研究确定了影响皮肤平滑肌肉瘤预后和治疗的人口统计学和病理因素。方法:从监测、流行病学和最终结果数据库中提取2000年至2020年皮肤平滑肌肉瘤患者的数据。使用倾向评分匹配和预后图来分析生存率预测。结果:患者以年龄≥65岁(50.5%)、男性(78.8%)、白人(88.5%)居多。总5年生存率为79.9%(95%可信区间[CI] = 77.4-82.6), 5年病因特异性生存率为95.7% (95% CI = 94.2-97.2)。基于治疗,仅手术的5年病因特异性生存率为82.9% (95% CI = 80.3-85.6),放疗和手术的5年病因特异性生存率为60.2% (95% CI = 47.7-76.0),未治疗的5年病因特异性生存率为68.2% (95% CI = 58.9-78.9)。多变量分析显示,头颈部肿瘤与较差的死亡率相关。结论:研究结果为未来皮肤平滑肌肉瘤的临床治疗方案的制定提供了有价值的见解,并影响了患者的护理和治疗效果。
Primary cutaneous leiomyosarcoma: demographics and survival benefit of surgical management in a US population.
Background: Leiomyosarcoma of the skin is a rare malignant mesenchymal neoplasm categorized as cutaneous or subcutaneous. This study identified demographic and pathological factors affecting the prognosis and treatment of leiomyosarcoma of the skin.
Methods: Data of patients with skin leiomyosarcoma was extracted from 2000 to 2020 using the Surveillance, Epidemiology, and End Results database. Propensity score matching and prognostic nomograms were used to analyze survival rate predictions.
Results: Most patients were >65 years of age (50.5%), male (78.8%), and White (88.5%). The overall 5-year survival was 79.9% (95% confidence interval [CI] = 77.4-82.6), and the 5-year cause-specific survival rate was 95.7% (95% CI = 94.2-97.2). Based on treatment, the 5-year cause-specific survival rate was 82.9% (95% CI = 80.3-85.6) for surgery only, 60.2% (95% CI = 47.7-76.0) for both radiation and surgery, and 68.2% (95% CI = 58.9-78.9) for no treatment. Multivariable analysis showed that head and neck tumors were associated with worse mortality.
Conclusion: The results provide valuable insights that could shape development of future clinical protocols for skin leiomyosarcoma and impact patient care and treatment efficacy.